System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Publications

Journal Article Ppublish 1 citation

PubMed: 42307153 DOI: 10.1016/j.jaccao.2026.05.008

Upper Extremity Deep Vein Thrombosis in Cancer Patients: Clinical Course by Cancer Site.

JACC CardioOncol 8(3):266-278

Authors: Olivier Espitia, Alexis F Guedon, Emma Courouve, Benjamin Brenner, Juan José López-Núñez, Romain Chopard, Alicia Lorenzo, Patricia Sigüenza, Son Truong Nguyen, Manuel Monreal

Affiliations

  • Department of Internal and Vascular Medicine, Nantes Université, CHU Nantes, l'Institut du Thorax, INSERM UMR 1087/CNRS UMR 6291, Team III Vascular & Pulmonary Diseases, Nantes, France.
  • Department of Internal, Sorbonne Université, AP-HP, Hôpital Saint Antoine, Paris, France.
  • Department of Internal and Vascular Medicine, Nantes Université, CHU Nantes, l'Institut du Thorax, INSERM UMR 1087/CNRS UMR 6291, Team III Vascular & Pulmonary Diseases, Nantes, France.
  • Department of Haematology and Bone Marrow Transplantation, Rambam Health Care Campus, Haifa, Israel.
  • Department of Internal Medicine, Hospital Germans Trias i Pujol, Badalona, Barcelona, Spain; Department of Medicine, Universitat Autònoma de Barcelona, Barcelona, Spain; Institut de Recerca Germans Trias i Pujol, Badalona, Barcelona, Spain; CIBER Enfermedades Respiratorias (CIBERES), Madrid, Spain.
  • Department of Cardiology, University Hospital Jean Minjoz, Besançon, France.
  • Department of Internal Medicine, Hospital Universitario La Paz, Madrid, Spain.
  • Department of Internal Medicine, Hospital Germans Trias i Pujol, Badalona, Barcelona, Spain.
  • Department of Hematology, Cho Ray Hospital, Ho Chi Minh City, Vietnam.
  • CIBER Enfermedades Respiratorias (CIBERES), Madrid, Spain; Faculty of Health Sciences, UCAM-Universidad Católica San Antonio de Murcia, Murcia, Spain.

Abstract

BACKGROUND

Upper extremity deep vein thrombosis (UEDVT) is common in patients with cancer. Data on recurrence and bleeding after cancer-associated UEDVT are limited.

OBJECTIVES

The objectives were to identify factors associated with venous thromboembolism (VTE) recurrence and bleeding in patients with cancer and UEDVT, overall and by cancer site, during and after anticoagulation.

METHODS

We analyzed patients from the Registro Informatizado de Pacientes con Enfermedad TromboEmbólica (RIETE), an international, prospective, observational registry of objectively confirmed VTE. We estimated cumulative incidence functions at 6, 12, 18, and 24 months and used proportional subdistribution hazard models to assess associations. Analyses were performed during and after discontinuation, using a landmark at the day of discontinuation if anticoagulation was stopped within 180 days or at day 180 if anticoagulation continued more than 180 days.

RESULTS

Of 5,195 patients with UEDVT, 2,210 had cancer. At 24 months, the cumulative incidence of recurrent VTE was 3.9% (95% CI: 3.1-4.9) in patients with cancer vs 2.5% (95% CI: 1.8-3.5) in those without cancer, and the cumulative incidence of bleeding was 6.8% (95% CI: 5.7-8.1) vs 4.3% (95% CI: 3.4-5.3), respectively (both P < 0.001). Among patients with cancer, 24-month recurrence varied by cancer site: lung, 6.4% (95% CI: 4.0-9.5); gastrointestinal, 4.0% (95% CI: 2.6-6.0); genitourinary, 3.6% (95% CI: 1.6-6.8); breast, 2.5% (95% CI: 1.2-4.5); and hematologic, 1.4% (95% CI: 0.5-3.4). During anticoagulation, lung cancer (subdistribution hazard ratio [sHR]: 10.1; 95% CI: 1.31-78.06) and younger age (per-year sHR: 0.97; 95% CI: 0.95-0.99) were associated with recurrence, whereas genitourinary cancer (sHR: 4.95; 95% CI: 1.16-21.17) and transient risk factors (sHR: 1.75; 95% CI: 1.16-2.64) were associated with bleeding. After anticoagulation discontinuation, 91 to 180 days (sHR: 0.49; 95% CI: 0.24-1.00) and more than 180 days (sHR: 0.35; 95% CI: 0.17-0.71) of anticoagulation were associated with lower recurrence vs 30 days or less.

CONCLUSIONS

Cancer-associated UEDVT carries higher risks of recurrence and bleeding than noncancer UEDVT. Lung cancer showed the greatest recurrence during treatment. Anticoagulation beyond 90 days was associated with a lower post-treatment recurrence. (Computerized Registry of Patients With Venous Thromboembolism [RIETE]; NCT02832245).

MeSH

Lung, Upper Extremity Deep Vein Thrombosis, Hemorrhage, Incidence, Neoplasms, Neoplasms By Site, Therapeutics, Venous Thromboembolism, Thrombosis, Veins